STILL’S DISEASE TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Still’s Disease Treatment Market - Drivers

Increasing awareness about Still’s disease

Increasing awareness campaigns in the field of Still’s disease are expected to drive the global Still’s disease treatment market growth over the forecast period. For instance, on September 7, 2022, AiArthritis, an International foundation for autoimmune and auto inflammatory arthritis, observed Still's Disease Awareness Day which was established by people, patients, and AiArthritis organization. The primary goal of this day is to increase awareness and education about Still's Disease (which includes both systemic Juvenile Idiopathic Arthritis/SJIA and Adult-Onset Still's Disease/AOSD) so an expedite diagnosis, improve disease management, and help patients explain their disease to others.

Global Still’s Disease Treatment Market: Restraints

Complications associated with Still’s disease

Complications, such as Macrophage Activation Syndrome (MAS), are expected to hamper the global Still’s disease treatment market growth. For instance, according to an article published by MDPI, a Switzerland-based healthcare publisher on October 24, 2022, explained the complications as the most severe complication of adult-onset Still’s disease is MAS. The prevalence ranges between 10% and 15% and is associated with a high mortality rate. Infections or medications, in combination with uncontrolled and prolonged inflammation in patients with a genetic predisposition, may cause this potentially fatal condition. MAS can occur either at the time of diagnosis or later on. Specific predictive or diagnostic factors are lacking for still’s disease. High fever, hepatosplenomegaly, cytopenias, coagulopathy, extreme hyperferritinemia, and hemophagocytosis on bone marrow aspirates are the most common symptoms of MAS.

To counterbalance this restraint, treatments on side effects and MAS should be introduced.